Se hai seguito il video riguardante la CHEMIOTERAPIA sul nostro canale youtube.com/almaphysio, potresti esserti chiesto se è fondato su evidente scientifiche o solo frutto dell’immaginazione.

Eccoti di seguito la lista degli articoli che puoi consultare per sapere le fonti delle affermazioni trasmesse:

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B

https://pubmed.ncbi.nlm.nih.gov/22863786/

The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies

https://pubmed.ncbi.nlm.nih.gov/15630849/

30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30383-7/fulltext

https://www.aph.gov.au/parliamentary_business/committees/senate/community_affairs/completed_inquiries/2004-07/cancer/report/index

Rethinking the war on cancer

https://pubmed.ncbi.nlm.nih.gov/24351321/

The War on Cancer: Lessons from the War on Terror

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202687/

Reducing the toxicity of cancer therapy: recognizing needs, taking action

https://pubmed.ncbi.nlm.nih.gov/22751283/

Is there such a thing as a cancer treatment that isn’t worth its cost?

https://pubmed.ncbi.nlm.nih.gov/22210088/

Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines

https://pubmed.ncbi.nlm.nih.gov/28033447/

Many FDA-approved cancer drugs might lack clinical benefit

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30954-3/fulltext

Do cancer drugs improve survival or quality of life?

https://www.bmj.com/content/359/bmj.j4528

Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs Approved Between 2011 and 2017

https://jamanetwork.com/journals/jamaoncology/fullarticle/2737068

Accelerated Approval of Cancer Drugs—Righting the Ship of the US Food and Drug Administration

https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2733557

The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses

https://pubmed.ncbi.nlm.nih.gov/26098871/

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2463590

Cancer drugs: high price, uncertain value

https://pubmed.ncbi.nlm.nih.gov/28978508/

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.

https://www.bmj.com/content/359/bmj.j4530

Hans Christian Andersen and the Value of New Cancer Treatments 

https://academic.oup.com/jnci/article/110/5/441/4735107

Saying No to Drugs: Fasting Protects Hematopoietic Stem Cells from Chemotherapy and Aging

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278638/

Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centr

https://pubmed.ncbi.nlm.nih.gov/25500146/